---
title: "Pre-market hot trades in US stocks: ATIF pre-market down 12.43%; Trilogy Mets pre-market up 8.75%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/261405051.md"
description: "ATIF pre-market down 12.43%; Trilogy Mets pre-market up 8.75%; Linkage Global pre-market up 245.45%; rYojbaba pre-market up 187.10%; Mira Pharmaceuticals pre-market up 78.03%"
datetime: "2025-10-16T09:27:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/261405051.md)
  - [en](https://longbridge.com/en/news/261405051.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/261405051.md)
---

# Pre-market hot trades in US stocks: ATIF pre-market down 12.43%; Trilogy Mets pre-market up 8.75%

**Pre-market Hot Trades in US Stocks**

ATIF is down 12.43% in pre-market trading. There have been no significant news recently; trading is active with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. The market is highly volatile, and risks should be monitored.

Trilogy Metals is up 8.75% in pre-market trading. According to recent important news:

1.  On October 14, trading of Trilogy Metals Inc. resumed after a brief halt. The halt was supervised by the Canadian Investment Regulatory Organization (CIRO), and after resuming trading, the market's attention on the stock significantly increased, leading to a pre-market price increase of 8.75%. Data source: CNW. Market trading is active, and volatility risks should be monitored.

**Top Gainers in Pre-market US Stocks**

Linkage Global is up 245.45% in pre-market trading, with no significant news recently. Trading is active with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

rYojbaba is up 187.10% in pre-market trading, with no significant news recently. Trading is active with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

MIRA is up 78.03% in pre-market trading. According to recent important news:

1.  On October 15, Mira Pharmaceuticals announced that its oral drug Mira-55 outperformed injectable morphine in a preclinical study, effectively restoring pain thresholds and reducing inflammation. This result supports the company's application for a new drug clinical trial, solidifying its position in the non-opioid pain relief market. This news significantly boosted the stock price.
    
2.  On October 16, Mira Pharmaceuticals' stock price rose 68.94% in after-hours trading, reflecting the market's positive response to its new drug research results.
    
3.  On October 16, Benzinga's stock ranking indicated that MIRA is in a consolidation phase in the short and medium term, but the long-term trend is upward, further enhancing investor confidence. The non-opioid pain relief market has huge potential, and volatility risks should be monitored

### Related Stocks

- [ZBAI.US](https://longbridge.com/en/quote/ZBAI.US.md)
- [TMQ.US](https://longbridge.com/en/quote/TMQ.US.md)
- [AUC.US](https://longbridge.com/en/quote/AUC.US.md)

## Related News & Research

- [Trilogy Metals Shareholders Reelect Board and Back Governance](https://longbridge.com/en/news/286442027.md)
- [Trilogy Metals welcomes transfer of ~1.4M acres of Dalton Corridor lands to Alaska](https://longbridge.com/en/news/285574103.md)
- [Trilogy Metals sets May 13, 2026 AGM; proxy statement filed with SEC](https://longbridge.com/en/news/280779693.md)
- [Trilogy Metals Inc. $TMQ Shares Bought by TSP Capital Management Group LLC](https://longbridge.com/en/news/271513932.md)
- [Trilogy Metals (NYSEAMERICAN:TMQ) Stock Price Crosses Below 50 Day Moving Average   - Should You Sell?](https://longbridge.com/en/news/270293280.md)